Adagio Raises $336 Million to Advance Covid-19 Antibody Treatment
An antibody startup Adagio Therapeutics announced the completion of a $336 million Series C financing round. The proceedings from the financing round will be used to augment the development of the company’s lead program developing treatments for COVID-19.
The company is working day and night to design a monoclonal antibody agent ADG20 that can both act as a therapeutic agent as well as a preventive measure. Not long ago, Adagio launched Phase I trial of the mAb in healthy volunteers. The company is also investigating the agent in pivotal Phase I/II/III trial in high-risk patients with mild o...
